BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with an increased risk for thromboembolic events. We investigated thrombin generation profiles in COPD patients and their dependence on plasma factor/inhibitor composition. METHODS: Factors (f) (fII, fV, fVII, fVIII, fIX, fX), antithrombin, protein C (PC) and free tissue factor pathway inhibitor (fTFPI) from 60 COPD patients (aged 64.2 ± 10.1 years; a mean forced expiratory volume in 1 second [FEV(1)], 55.6 ± 15.8% of predicted values) were compared with those for 43 controls matched for age, sex, weight and smoking. Patients receiving anticoagulation were excluded. Using each individual's plasma coagulation protein composition, tissue factor-initiated thrombin generation was assessed computationally. RESULTS: COPD patients had higher fII (115 ± 16 vs 102 ± 10%, p < 0.0001), fV (114 ± 19 vs 102 ± 12%, p = 0.0002), fVII (111 ± 15 vs 102 ± 17%, p = 0.002), fVIII (170 ± 34 vs 115 ± 27%, p < 0.0001), and fIX (119 ± 21 vs 107 ± 17%, p = 0.003), and lower fTFPI (17.7 ± 3.2 vs 18.9 ± 3.2 ng/ml, p = 0.047) compared with controls, while fX, antithrombin, and PC were similar in both groups. Computational thrombin generation profiles showed that compared with controls, COPD patients had higher maximum thrombin levels (+28.3%, p < 0.0001), rates of thrombin generation (+46.1%, p < 0.0001) and total thrombin formation (+14.4%, p < 0.001), together with shorter initiation phase of thrombin generation (p < 0.0001) and the time to maximum thrombin levels (p < 0.0001). Thrombin generation profiles in COPD patients can be normalized via correction of fII, fVIII , fIX and TFPI. The severity of COPD and inflammatory markers were not associated with thrombin generation profiles. CONCLUSIONS: Prothrombotic phenotype in COPD patients is largely driven by increased prothrombin, fVIII, fIX, and lower fTFPI.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is associated with an increased risk for thromboembolic events. We investigated thrombin generation profiles in COPDpatients and their dependence on plasma factor/inhibitor composition. METHODS: Factors (f) (fII, fV, fVII, fVIII, fIX, fX), antithrombin, protein C (PC) and free tissue factor pathway inhibitor (fTFPI) from 60 COPDpatients (aged 64.2 ± 10.1 years; a mean forced expiratory volume in 1 second [FEV(1)], 55.6 ± 15.8% of predicted values) were compared with those for 43 controls matched for age, sex, weight and smoking. Patients receiving anticoagulation were excluded. Using each individual's plasma coagulation protein composition, tissue factor-initiated thrombin generation was assessed computationally. RESULTS:COPDpatients had higher fII (115 ± 16 vs 102 ± 10%, p < 0.0001), fV (114 ± 19 vs 102 ± 12%, p = 0.0002), fVII (111 ± 15 vs 102 ± 17%, p = 0.002), fVIII (170 ± 34 vs 115 ± 27%, p < 0.0001), and fIX (119 ± 21 vs 107 ± 17%, p = 0.003), and lower fTFPI (17.7 ± 3.2 vs 18.9 ± 3.2 ng/ml, p = 0.047) compared with controls, while fX, antithrombin, and PC were similar in both groups. Computational thrombin generation profiles showed that compared with controls, COPDpatients had higher maximum thrombin levels (+28.3%, p < 0.0001), rates of thrombin generation (+46.1%, p < 0.0001) and total thrombin formation (+14.4%, p < 0.001), together with shorter initiation phase of thrombin generation (p < 0.0001) and the time to maximum thrombin levels (p < 0.0001). Thrombin generation profiles in COPDpatients can be normalized via correction of fII, fVIII , fIX and TFPI. The severity of COPD and inflammatory markers were not associated with thrombin generation profiles. CONCLUSIONS: Prothrombotic phenotype in COPDpatients is largely driven by increased prothrombin, fVIII, fIX, and lower fTFPI.
Authors: R Vormittag; P Bencur; C Ay; T Tengler; T Vukovich; P Quehenberger; C Mannhalter; I Pabinger Journal: J Thromb Haemost Date: 2006-11-28 Impact factor: 5.824
Authors: Suellen M Curkendall; Cynthia DeLuise; Judith K Jones; Stephan Lanes; Mary Rose Stang; Earl Goehring; Dewei She Journal: Ann Epidemiol Date: 2005-07-21 Impact factor: 3.797
Authors: Sarah Goldman; Shannon M Prior; Jan P Bembenek; Maciej Niewada; Elżbieta Broniatowska; Anna Członkowska; Saulius Butenas; Anetta Undas Journal: J Thromb Thrombolysis Date: 2017-10 Impact factor: 2.300
Authors: Anta Ngkelo; Roland F Hoffmann; Andrew L Durham; John A Marwick; Simone M Brandenburg; Harold G de Bruin; Marnix R Jonker; Christos Rossios; Eleni Tsitsiou; Gaetano Caramori; Marco Contoli; Paolo Casolari; Francesco Monaco; Filippo Andò; Giuseppe Speciale; Iain Kilty; Kian F Chung; Alberto Papi; Mark A Lindsay; Nick H T Ten Hacken; Maarten van den Berge; Wim Timens; Peter J Barnes; Antoon J van Oosterhout; Ian M Adcock; Paul A Kirkham; Irene H Heijink Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-08-28 Impact factor: 5.464
Authors: Jason V Baker; Kathleen Brummel-Ziedins; Jacqueline Neuhaus; Daniel Duprez; Nathan Cummins; David Dalmau; Jack DeHovitz; Clara Lehmann; Ann Sullivan; Ian Woolley; Lewis Kuller; James D Neaton; Russell P Tracy Journal: J Am Heart Assoc Date: 2013-07-29 Impact factor: 5.501
Authors: Kathleen E Brummel-Ziedins; Matthew Gissel; Jacqueline Neuhaus; Álvaro H Borges; David R Chadwick; Sean Emery; James D Neaton; Russell P Tracy; Jason V Baker Journal: Res Pract Thromb Haemost Date: 2018-09-11